0000899243-19-010984.txt : 20190423
0000899243-19-010984.hdr.sgml : 20190423
20190423161523
ACCESSION NUMBER: 0000899243-19-010984
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190423
FILED AS OF DATE: 20190423
DATE AS OF CHANGE: 20190423
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Stagg Robert
CENTRAL INDEX KEY: 0001735050
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35993
FILM NUMBER: 19761718
MAIL ADDRESS:
STREET 1: C/O ONCOMED PHARMACEUTICALS, INC.
STREET 2: 800 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: OncoMed Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001302573
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 383572512
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 800 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 650-995-8200
MAIL ADDRESS:
STREET 1: 800 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-04-23
1
0001302573
OncoMed Pharmaceuticals Inc
OMED
0001735050
Stagg Robert
C/O ONCOMED PHARMACEUTICALS, INC.
800 CHESAPEAKE DRIVE
REDWOOD CITY
CA
94063
0
1
0
0
See Remarks
Common Stock
2019-04-23
4
U
0
28917
D
0
D
On April 23, 2019, pursuant to the Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of December 5, 2018, by and among Mereo Biopharma Group PLC ("Mereo"), Mereo US Holdings Inc., Mereo Mergerco One Inc. ("Merger Sub") and the Issuer, Merger Sub merged with and into the Issuer, with the Issuer surviving as an indirect wholly-owned subsidiary of Mereo (the "Merger"). Pursuant to the Merger, the Issuer's stockholders received the right to receive (i) a certain number of American Depositary Shares, each representing five ordinary shares, 0.003 pounds par value per share, of Mereo and (ii) one contingent value right, which represents the contractual right to receive contingent payments if specified milestones are achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated April 23, 2019, by and among Computershare Inc. and Mereo (the "Merger Consideration") for each share of the Issuer's stock that they own.
(Continued from footnote 1) Pursuant to the Merger, the Reporting Person disposed of all shares of Issuer common stock beneficially owned by it, and received the Merger Consideration for each share of Issuer common stock.
Senior Vice President, Clinical Research and Development
/s/ Alicia Hager, Attorney-in-Fact for Robert Stagg
2019-04-23